Celldex Therapeutics, Inc. financial data

Symbol
CLDX on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
53 Frontage Road, Suite 220, Hampton, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Former names
AVANT IMMUNOTHERAPEUTICS INC (to 9/29/2008), T CELL SCIENCES INC (to 8/21/1998)
Latest financial report
Q1 2024 - May 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.76 K % +7.7%
Debt-to-equity 6.81 % -17%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.9 M shares +39.5%
Common Stock, Shares, Outstanding 65.9 M shares +39.5%
Entity Public Float 1.6 B USD +23.1%
Common Stock, Value, Issued 66 K USD +40.4%
Weighted Average Number of Shares Outstanding, Basic 58.9 K shares +24.7%
Weighted Average Number of Shares Outstanding, Diluted 58.9 K shares +24.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 6.07 M USD +92.8%
Research and Development Expense 123 M USD +33.6%
General and Administrative Expense 33.4 M USD +24%
Costs and Expenses 169 M USD +32.3%
Operating Income (Loss) -163 M USD -30.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -141 M USD -25.9%
Earnings Per Share, Basic -2.86 USD/shares -13%
Earnings Per Share, Diluted -2.86 USD/shares -13%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 115 M USD +113%
Marketable Securities, Current 709 M USD +216%
Assets, Current 835 M USD +188%
Property, Plant and Equipment, Net 4.06 M USD +1.65%
Operating Lease, Right-of-Use Asset 2.17 M USD -40.4%
Intangible Assets, Net (Excluding Goodwill) 27.2 M USD 0%
Other Assets, Noncurrent 107 K USD +2.89%
Assets 869 M USD +168%
Accounts Payable, Current 3.23 M USD -4.15%
Employee-related Liabilities, Current 9.35 M USD +24.2%
Accrued Liabilities, Current 17.5 M USD +87.1%
Liabilities, Current 26.3 M USD +72.8%
Operating Lease, Liability, Noncurrent 470 K USD -78.2%
Other Liabilities, Noncurrent 3.47 M USD -21.1%
Liabilities 30.2 M USD +38.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.24 M USD +5.7%
Retained Earnings (Accumulated Deficit) -1.43 B USD -11.3%
Stockholders' Equity Attributable to Parent 839 M USD +177%
Liabilities and Equity 869 M USD +168%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.6 M USD -42.2%
Net Cash Provided by (Used in) Financing Activities 436 M USD +62740%
Net Cash Provided by (Used in) Investing Activities -315 M USD -700%
Common Stock, Shares Authorized 297 M shares 0%
Common Stock, Shares, Issued 65.9 M shares +39.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 80.3 M USD +225%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 115 M USD +113%
Deferred Tax Assets, Valuation Allowance 347 M USD +11.1%
Deferred Tax Assets, Gross 353 M USD +10.9%
Operating Lease, Liability 2.54 M USD -37%
Payments to Acquire Property, Plant, and Equipment 344 K USD -41.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -145 M USD -24.1%
Lessee, Operating Lease, Liability, to be Paid 2.74 M USD -39.8%
Property, Plant and Equipment, Gross 26.4 M USD +4.23%
Operating Lease, Liability, Current 1.64 M USD +10.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 949 K USD -49.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.79 M USD +0.68%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 195 K USD -62.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 896 K USD +1127%
Deferred Tax Assets, Operating Loss Carryforwards 198 M USD +4.97%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 3 M shares 0%
Operating Lease, Payments 2 M USD +5.26%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 775 K USD +6.75%
Share-based Payment Arrangement, Expense 26.8 M USD +59.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%